The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!


Variant: NM_000152.5(GAA):c.281_282del (p.Pro94fs)

CA16041881

370458 (ClinVar)

Gene: GAA (HGNC:2548)
Condition: glycogen storage disease II (MONDO:0009290)
Inheritance Mode: Autosomal recessive inheritance
UUID: 9c3f906c-869b-4686-9b9b-c498c12a2e14
Approved on: 2026-08-04
Published on: 2026-08-04

HGVS expressions

NM_000152.5(GAA):c.281_282del (p.Pro94fs)
NM_000152.5:c.281_282del
NC_000017.11:g.80104867_80104868del
CM000679.2:g.80104867_80104868del
NC_000017.10:g.78078666_78078667del
CM000679.1:g.78078666_78078667del
NC_000017.9:g.75693261_75693262del
NG_009822.1:g.8312_8313del
ENST00000570803.6:c.281_282del
ENST00000572080.2:c.281_282del
ENST00000577106.6:c.281_282del
ENST00000302262.8:c.281_282del
ENST00000302262.7:c.281_282del
ENST00000390015.7:c.281_282del
ENST00000570803.5:c.281_282del
ENST00000577106.5:c.281_282del
NM_000152.3:c.281_282del
NM_001079803.1:c.281_282del
NM_001079804.1:c.281_282del
NM_000152.4:c.281_282del
NM_001079803.2:c.281_282del
NM_001079804.2:c.281_282del
NM_001079803.3:c.281_282del
NM_001079804.3:c.281_282del
More

Likely Pathogenic

Met criteria codes 2
PM2_Supporting PVS1
Not Met criteria codes 2
PP4 PM3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2.0

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
The NM_000152.5:c.281_282del (p.Pro94ArgfsTer51) variant in GAA is a frameshift variant predicted to cause a premature stop codon in exon 2 out of a total of 20 exons, leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). At least two possible patients have been reported with this variant, one with cardiomyopathy and/or arrhythmia, but no additional details available (PMID: 35947370), and at least one patient who is asymptomatic, with elevated CK (level unknown), positive family history (PMID: 34020684, 34305788). There is insufficient evidence available to apply PP4. At least one patient is compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen LD VCEP, c.-32-13G>T. However, given that the patient is asymptomatic, other than elevated CK (no further details available) (PMID: 34020684, 34305788; possibly the same patient/family member), this data will not be counted for PM3. The highest population minor allele frequency in gnomAD v4.1.0. is 0.00003 (2/60004 alleles) in the Admixed American population, which is lower than the ClinGen LD VCEP's threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 370458). The classification of this variant has been upgraded from Variant of Uncertain Significance to Likely Pathogenic based on the recommendations of the ClinGen Sequence Variant Interpretation Working Group, that a variant meeting PVS1 and PM2_Supporting is classified as Likely Pathogenic (https://clinicalgenome.org/site/assets/files/5182/pm2_-_svi_recommendation_-_approved_sept2020.pdf ). In summary, this variant meets the criteria to be classified as Likely Pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0): PVS1, PM2_Supporting. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on August 4, 2026)
Met criteria codes
PM2_Supporting
The highest population minor allele frequency in gnomAD v4.1.0. is 0.00003 (2/60004 alleles) in the Admixed American population, which is lower than the ClinGen LD VCEP's threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting).
PVS1
The NM_000152.5:c.281_282del (p.Pro94ArgfsTer51) variant in GAA is a frameshift variant predicted to cause a premature stop codon in exon 2 out of a total of 20 exons, leading to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1).
Not Met criteria codes
PP4
At least two possible patients have been reported with this variant, one with cardiomyopathy and/or arrhythmia, but no additional details available (PMID: 35947370), and at least one patient who is asymptomatic, with elevated CK (level unknown), positive family history (PMID: 34020684, 34305788). There is insufficient evidence available to apply PP4.
PM3
At least one patient is compound heterozygous for the variant and another variant in GAA that has been classified as pathogenic by the ClinGen LD VCEP, c.-32-13G>T. However, given that the patient is asymptomatic, other than elevated CK (no further details available) (PMID: 34020684, 34305788; possibly the same patient/family member), this data will not be counted for PM3.
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
ClinGen Terms of Use.
¤ Powered by BCM's Genboree.